<DOC>
	<DOCNO>NCT00015938</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combine docetaxel , vinorelbine , filgrastim treat woman stage IV breast cancer .</brief_summary>
	<brief_title>S0102 : Docetaxel , Vinorelbine , Filgrastim Treating Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine 1-year survival woman HER-2-negative stage IV breast cancer treat docetaxel , vinorelbine , filgrastim ( G-CSF ) . - Determine response rate ( complete partial response ) time progression patient treat regimen . - Determine qualitative quantitative toxic effect regimen patient population . OUTLINE : This multicenter study . Patients receive docetaxel IV 1 hour day 1 , vinorelbine IV 6-10 minute day 8 15 , filgrastim ( G-CSF ) subcutaneously day 2-21 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 6 month 3 year . PROJECTED ACCRUAL : A total 90 patient accrue study within 4-5 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV carcinoma breast HER2 negative 0 1+ DAKO ( 2+ DAKO allow fluorescence situ hybridization [ FISH ] negative ) Weak stain immunohistochemistry test No amplification FISH No effusion ascites site disease No brain CNS disease metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Not specify Performance status : Zubrod 02 Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT SGPT great 1.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Not specify Other : No clinically significant preexist grade 2 great motor sensory peripheral neuropathy unless due cancer No known sensitivity E. coliderived proteins No prior severe hypersensitivity reaction drug formulate polysorbate 80 No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy 1 prior adjuvant neoadjuvant chemotherapy program primary disease At least 6 month since prior chemotherapy Prior adjuvant anthracycline allow No prior taxanes ( docetaxel paclitaxel ) Endocrine therapy : Prior adjuvant hormonal therapy metastatic disease allow No concurrent hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy Surgery : At least 2 week since prior surgery recover</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>